Here's a suggested design intervention to more accurately position a drug product.
The leaked SCOTUS draft opinion on rescinding Roe v. Wade provoked another look at product branding and the innate prejudices inherent in the package design for what is tag-lined "The Early Option Pill." Men bear half the responsibility for the condition. The existing Mifeprex package art focuses solely on a lone female's arm directed at the womb, a gender-specific marketing signal which ignores the father. I've updated the illustration and added a masculine figure with post-coital penis, his arm directed toward the reproductive regions. The revised treatment is a more accurate product-specific depiction of the drug's actual audience.